Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579248 · ClinicalTrials.gov registry record · Early Phase 1
Intraoral Hypothermia Device for Preserving Taste During Radiation
A Early Phase 1 study of Head and Neck Cancer and Radiation Therapy, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06579248 is a Early Phase 1 study of Head and Neck Cancer and Radiation Therapy that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 15 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06579248, a Early Phase 1 study of Head and Neck Cancer and Radiation Therapy, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatments to preserve or lower the decline of taste function.
Conditions Studied
Interventions
- DEVICE Intraoral Device
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-08-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06579248
The ClinicalTrials.gov registry entry for NCT06579248 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Intraoral Device is the first listed.
NCT06579248 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06579248 about?
NCT06579248 is a clinical study titled "Intraoral Hypothermia Device for Preserving Taste During Radiation". Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatm...
What is the current status of trial NCT06579248?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2024-11-12. Estimated completion is 2026-08-30.
What conditions does trial NCT06579248 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Radiation Therapy, Taste Dysfunction.
What interventions are being tested in trial NCT06579248?
The interventions under investigation include: Intraoral Device (DEVICE).
Who is sponsoring clinical trial NCT06579248?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06579248 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
RECRUITING · Early Phase 1
-
Smoking Cessation Treatment for Head & Neck Cancer Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
COMPLETED · Early Phase 1
-
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
COMPLETED · Early Phase 1
-
Curcumin Biomarker Trial in Head and Neck Cancer
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.